People First Radio – June 26, 2025People First Radio – June 26, 2025
People First Radio
Guests examine how psychedelics are moving into medical and corporate settings, questioning who gains and who is left out. The discussion weighs therapeutic promise against hype, access barriers, and the risk of profit-driven models for people seeking mental health and addiction support.
0:00•27 Jun 2025
Psychedelic Therapy, Big Business, and the Fight for Fair Access
Episode Overview
- Psychedelics are highly dependent on set and setting, and do not guarantee positive or progressive outcomes on their own.
- Current legal access in Canada centres on prescribed ketamine, special access to psilocybin and MDMA, and research participation, with many people turning to an underground market.
- Corporate and pharmaceutical models can strip out psychotherapy and integration, risking harm by turning psychedelics into quick, profit-driven products.
- Hype, high expectations, and serious research limitations (such as weak blinding and narrow trial populations) may overstate benefits and underplay harms.
- Guests call for patient-centred, accessible, and spiritually aware approaches, aiming for a middle ground between rigid regulation and unsafe deregulation.
“"Psychedelics were never meant to be offered as a band-aid approach... like some kind of magic pill. They are an amplifier to a larger therapeutic process."”
Curious about how others navigate their sobriety journey? This edition of People First Radio digs into the rise of psychedelic-assisted therapy and asks who really benefits when these powerful substances meet big business. Host Joe Pugh talks with authors and academics Jamie Brownlee and Kevin Walby about their book *Psychedelic Capitalism*. They trace how psilocybin, MDMA and ketamine have moved from underground and sacred settings into glossy clinics and clinical trials.
Brownlee stresses that psychedelics are "highly context dependent" and warns against the idea that they automatically create kinder, fairer societies. Instead, the pair question whether corporate models and pharmaceutical interests are shaping psychedelics into yet another quick-fix product. If you're in recovery or thinking about psychedelic therapy, you'll hear a grounded breakdown of how access currently works in Canada.
Vancouver Island University’s psychedelics chair, Shannon Dames, outlines three legal routes – prescribed ketamine, special access programmes for psilocybin and MDMA, and research participation – plus a rapidly growing underground scene. She highlights a hard truth: "Psychedelics were never meant to be offered as a band-aid approach... like some kind of magic pill.
They are an amplifier to a larger therapeutic process." The conversation keeps circling back to set and setting, spiritual care, and the risk of stripping out therapy and integration in favour of faster, cheaper, high-volume clinics. Ketamine chains, aggressive marketing, and investor pressure all come under scrutiny, especially for people already struggling with mental health and addiction.
Rather than offering neat answers, the episode asks what a fair, accessible, and genuinely healing psychedelic system might look like – one that doesn’t "incentivise sickness" or deepen inequality. If you're wondering whether psychedelics are a hopeful tool, a risky shortcut, or both, this discussion gives plenty to think about. What kind of support and safeguards would you want in place before psychedelics became part of mainstream mental health care?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.